Oncomine cfNA Assays for Clinical Oncology Research

Liquid biopsy – a transformative tool for clinical oncology research

Liquid biopsy testing refers to the non-invasive analysis of tumor-derived genomic material found in the blood or other biofluids, such as bile, cerebro-spinal fluid, or urine.

 

Liquid biopsies offer several advantages and can deliver a relevant genomic profile even if a tissue sample is unavailable, or complement tissue samples to understand tumor heterogeneity.

Oncomine liquid biopsy solutions for clinical oncology research

We offer a range of Oncomine cfNA liquid biopsy assays for applications across a spectrum of disease research areas.

 

Each assay enables relevant insights into the genomic makeup of tumors and is provided as part of a complete solution on 2 amplicon-based next-generation sequencing (NGS) platforms, the Ion GeneStudio S5 System and the Ion Torrent Genexus System.

 

Integrated analysis software helps enhance the efficiency of reporting and the interpretation of your NGS results.

 

The highly automated workflow helps simplify the testing process, allowing minimal hands-on time and making NGS testing accessible to laboratories of almost all levels of experience and expertise.

Multi-biomarker DNA and RNA insights in 1 to 3 days from a single tube of blood

Reporting solutions include Oncomine Reporter, the laboratory's own software, or other third-party software.

> Simultaneous analysis of cfDNA (relevant SNVs, indels and CNVs) and cfRNA (fusions to test for all relevant biomarkers)

 

> Reliable results from multiple sample sources: Such as ctNA from blood, bile, cerebrospinal fluid, and urine

 

> Low sample input requirements of as little as 1 ng of total cell-free nucleic acid and high sensitivity with 0.1% LOD to detect even low-level variants

> End-to-end highly automated workflow with as little as 20 min hands on time (HOT) to help reduce complexity of implementation and maintenance, needs for bioinformatics expertise and potentially save your technicians' time

 

> Typical turnaround time (TAT) of 1-3 days to enable you to deliver relevant reports with speed  

The Oncomine cfNA assay portfolio

Multi-cancer and tumor-type specific gene coverage to fit your lab’s needs.

Oncomine

Precision
Assay

 

Oncomine Pan-Cancer Cell-Free Assay

Oncomine
Lung cfTNA

Assay

Oncomine Breast cfDNA

Assay v2

Oncomine

Colon cfDNA

Assay

Assay portfolio gene content

 

Multi-cancer
Oncomine Precision Assay
SVNs/Indels CNVs Fusions
AKT1 CDKN2A FGFR1 HRAS MTOR RAF1 ALK FGFR1 ALK FGFR3 RET
AKT2 CHEK2 FGFR2 IDH1 NRAS RET AR FGFR2 AR MET ROS1
AKT3 CTNNB1 FGFR3 IDH2 NTRK1 ROS1 CD274 FGFR3 BRAF NRG1 RSPO2
ALK EGFR FGFR4 KIT NTRK2 SMO CDKN2A KRAS EGFR NTRK1 RSPO3
AR ERBB2 FLT3 KRAS NTRK3 TP53 EGFR MET ESR1 NTRK2  
ARAF ERBB3 GNA11 MAP2K1 PDGFRA   ERBB2 PIK3CA FGFR1 NTRK3  
BRAF ERBB4 GNAQ MAP2K2 PIK3CA   ERBB3 PTEN FGFR2 NUTM1  
CDK4 ESR1 GNAS MET PTEN            

 

Oncomine Pan-Cancer Cell-Free Assay
SVNs/Indels CNVs Fusions
AKT1 CTNNB1 FGFR1 GNAS MAP2K2 PIK3CA SMO CCND1 FGFR1 ALK MET
ALK DDR2 FGFR2 HRAS MET PTEN TP53 CCND2 FGFR2 BRAF NTRK1
APC EGFR FGFR3 IDH1 MTOR RAF1   CCND3 FGFR3 ERG NTRK3
AR ERBB2 FGFR4 IDH2 NRAS RET   CDK4 MET ETV1 RET
ARAF ERBB3 FLT3 KIT NTRK1 ROS1   CDK6 MYC FGFR1 ROS1
BRAF ESR1 GNA11 KRAS NTRK3 SF3B1   EGFR   FGFR2  
CHEK2 FBXW7 GNAQ MAP2K1 PDGFRA SMAD4   ERBB2   FGFR3  
Lung Breast Colon
Oncomine cfTNA Assay Oncomine Breast cfDNA Assay v2 Oncoine Colon cfDNA Assay
ALK KRAS PIK3CA AKT1 ERBB3 KRAS AKT1 ERBB2 NRAS
BRAF MAP2K1 RET CCND1 ESR1 PIK3CA APC FBXW7 PIK3CA
EGFR MET ROS1 EGFR FBXW7 SF3B1 BRAF GNAS SMAD4
ERBB2 NRAS TP53 ERBB2 FGFR1 TP53 CTNNB1 KRAS TP53
            EGFR MAP2K1  

On Demand Webinar: Oncomine Precision Assay: Automated and decentralized genomic profiling of plasma cell-free DNA

Hear Dr. Ting Chan, PhD from the University of Melourne at OncomineWorld as she discusses the benefits of using liquid biopsy NGS for oncology research. 

Dr. Ting Chan, PhD

Curation Scientist, Centre for Cancer Research

University of Melbourne
Melbourne, Australia

Experiences of Oncomine cfNA assay users

Dr. Brandon Sheffield, MD

Pathologist, W. Osler Health System, Brampton, Ontario

“The Oncomine Precision Assay, is novel…in that it also looks at circulating cell-free tumor derived RNA to detect fusions as opposed to most of the commercially available assays, which are looking only at DNA.”

Beatriz Bellosillo, PhD

Hospital del Mar, Spain

“Genomic heterogeneity after anti-EGFR therapy was successfully detected in 94% of the metastatic colorectal cancer research samples using a next-generation sequencing multi-biomarker approach. The Oncomine Colon cfDNA Assay enabled detection of somatic mutations with MAF >0.1%.

Ordering information

Ready to speak to a Thermo Fisher representative?

We will be happy to answer your questions and provide a demo of our NGS solutions.

For Research Use Only. Not for use in diagnostic procedures.